## miR-489 inhibits silica-induced pulmonary fibrosis by targeting MyD88 and Smad3 and is negatively regulated by lncRNA CHRF

Qiuyun Wu<sup>1,†</sup>, Lei Han<sup>1,2,†</sup>, Weiwen Yan<sup>1,†</sup>, Xiaoming Ji<sup>1</sup>, Ruhui Han<sup>1</sup>, Jingjin Yang<sup>1</sup>, Jiali Yuan<sup>1</sup>, Chunhui Ni<sup>1,\*</sup>

<sup>1</sup> Department of Occupational Medicine and Environmental Health, Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China.

<sup>2</sup> Institute of Occupational Disease Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.

<sup>†</sup>These authors contributed equally to this work.

## \* Corresponding authors

<sup>\*</sup> Correspondence to: Department of Occupational Medicine and Environmental Health, Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing 211166, China. Tel: +86 25 86868418; Fax: +86 25 86868499; Email: chni@njmu.edu.cn, chninjmu@126.com



**Figure S1. miR-489 is decreased in mouse lung tissues in a model of silica-induced pulmonary fibrosis.** The C57BL/6 mice were sacrificed on day 3, 7, 14, 28 or 56 after intratracheal instillation of silica suspended saline and saline. The fold changes of miR-489 in mouse lung tissues were determined by microRNA (miRNA, miR) microarray with total RNA analysis.



Figure S2. miR-489 suppresses inflammation by targeting MyD88 in differentiated THP-1 cells. (A) qRT-PCR analysis of miR-489 levels in differentiated THP-1 cells treated with different doses of silica for 12 h with \*\*P<0.01 vs. the dose 0 group. (B) Western blot analysis of MyD88, IL-1 $\beta$  and TGF- $\beta$ 1 expression in differentiated THP-1 cells transfected with miR-489 mimic with \*\*P<0.01 vs. the silica plus mimic-NC group. (C) Western blot analysis of MyD88, IL-1 $\beta$  and TGF- $\beta$ 1 expression in differentiated THP-1 cells transfected with siRNA against MyD88 for 24 h with \*\*P<0.01 vs. the silica plus siRNA-NC group. All data are expressed as the means ± SD of at least three independent experiments.



**Figure S3. miR-489 suppresses fibrotic biomarkers by targeting Smad3.** (A) Western blot analysis of α-SMA and Vimentin expression in NIH/3T3 cells treated with 1 ng/ml TGF-β1 for 24 and 48 h with \*\*P<0.01 vs. the control group. (B) Immunofluorescence images of α-SMA expression in NIH/3T3 cells treated with 1 ng/ml TGF-β1 for 48 h. (C) Western blot analysis of α-SMA and Vimentin expression in NIH/3T3 cells transfected with miR-489 mimic with \*\*P<0.01 vs. the TGF-β1 plus mimic-NC group. (D) Western blot analysis of α-SMA and Vimentin expression in NIH/3T3 cells transfected with siRNA against Smad3 for 24 h with \*\*P<0.01 vs. the TGF-β1 plus siRNA-NC group. All data are expressed as the means  $\pm$  SD of at least three independent experiments.



**Figure S4. miR-489 suppresses fibroblast differentiation by targeting Smad3 in human fibroblasts (MRC-5). (A)** qRT-PCR analysis of miR-489 levels in human fibroblasts (MRC-5) treated with different doses of TGF-β1 for 24 and 48 h with \**P*<0.05 and \*\**P*<0.01 vs. the dose 0 group. (**B-C**) Western blot analysis of total Smad3, p-Smad3, α-SMA and Vimentin expression in MRC-5 cells transfected with miR-489 mimic with \*\**P*<0.01 vs. the TGF-β1 plus mimic-NC group. (**D-E**) Western blot analysis of total Smad3, p-Smad3, α-SMA and Vimentin expression in MRC-5 cells transfected with siRNA against Smad3 for 24 h with \*\**P*<0.01 vs. the TGF-β1 plus siRNA-NC group. All data are expressed as the means  $\pm$  SD of at least three independent experiments.



Figure S5. The lncRNA CHRF negatively regulates miR-489 expression in fibroblasts. (A) qRT-PCR analysis of CHRF levels in NIH/3T3 cells treated with different doses of TGF- $\beta$ 1 for 24 and 48 h with \**P*<0.05 and \*\**P*<0.01 vs. the dose 0 group. (B) qRT-PCR analysis of miR-489 levels in NIH/3T3 cells transfected with miR-489 mimic or co-transfected with miR-489 mimic and pUC57 plasmids of CHRF with \*\**P*<0.01 vs. the miR-489 mimic group. (C) qRT-PCR analysis of miR-489 levels in NIH/3T3 cells transfected with miR-489 mimic or co-transfected with miR-489 mimic and siRNA against CHRF with \*\**P*<0.01 vs. the miR-489 mimic group. All data are expressed as the means ± SD of at least three independent experiments.



Figure S6. The IncRNA CHRF promotes silica-induced elevation of fibrotic biomarkers through targeting miR-489. (A) Western blot analysis of  $\alpha$ -SMA and Vimentin expression in NIH/3T3 cells transfected with pUC57 plasmids of CHRF with \*\*P<0.01 vs. the TGF- $\beta$ 1 plus pUC57-NC group. (B) Western blot analysis of  $\alpha$ -SMA and Vimentin expression in NIH/3T3 cells transfected with siRNA against CHRF with \*\*P<0.01 vs. the TGF- $\beta$ 1 plus siRNA-NC group. (C) Western blot analysis of  $\alpha$ -SMA and Vimentin expression in NIH/3T3 cells co-transfected with miR-489 mimic and CHRF plasmids with \*\*P<0.01 vs. the TGF- $\beta$ 1 plus miR-489 mimic and pUC57-NC group. (D) Western blot analysis of  $\alpha$ -SMA and Vimentin expression in NIH/3T3 cells co-transfected with miR-489 mimic and siRNA against CHRF with \*\*P<0.01 vs. the TGF- $\beta$ 1 plus miR-489 mimic and siRNA against CHRF with \*\*P<0.01 vs. the TGF- $\beta$ 1 plus miR-489 mimic and siRNA against CHRF with \*\*P<0.01 vs. the TGF- $\beta$ 1 plus miR-489 mimic and siRNA against CHRF with \*\*P<0.01 vs. the TGF- $\beta$ 1 plus miR-489 mimic and siRNA against